Magnasense logotype


Brand Change Announcement: AegirBio AB has officially changed its name to Magnasense AB. The new website,, launched on 9 July 2024, with redirects from

Aegirbio AB ensures production capacity

In cooperation with third-party suppliers, Aegirbio has ensured the ability to deliver up to 9,000,000 tests per month as of August. These measures were implemented to make sure that the company is able to meet the great demand that it sees for its products at the moment.

The need for simple and safe tests to control the spread of infection in countries where the vaccination rollout is less well advanced than for example in Europe is gigantic. In order to keep infrastructure, tourism, schools, workplaces and other venues open, countries in the region are carrying out widespread testing efforts, and thus look for products that are easy to administer and provide reliable results. Aegirbio’s COVID-19 test has been selected for its simple test procedure, which allows it to be used for everything from small children at school to workplaces where it is important to conduct frequent sampling, and where nasal testing is unable to achieve sufficiently wide testing coverage.

“It is extremely important for us to secure the production now, given that the demand for our tests is so enormous! Now that production is scaled up properly, we are able to reinforce our focus on making sales,” says Martin Linde, CEO of Aegirbio.

For more information, please contact:

Anders Ingvarsson, SO Aegirbio AB
Telephone: +46 706 791 878

Martin Linde, CEO Aegirbio AB
Telephone: +46 706 730 968

Aegirbio is a Swedish diagnostics company established to offer tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; a quarter of all drugs are projected to be biological in 2020. At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.

The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment, while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs, suboptimal clinical outcomes, and a higher proportion of patients suffering severe side effects.

The Company has completed acquisitions that ensure long-term access to key technologies and open up new application areas. Through these acquisitions, Aegirbio, rooted in laboratory testing, have in a short period of time added technologies and skills to the Company to make headway towards becoming the multidiagnostic company it has set out to be.

Aegirbio is now building its operations around technologies for

  • Rapid testing for indicative and quick results
  • Point of Need, quantitative home tests for chronic diseases
  • Point of Care, quantitative point-of-care tests for routine controls in clinics and health centres
  • Laboratory tests for monitoring patients treated with biological drugs.

The acquisitions provide the Company the means to develop new diagnostics to enable people to monitor their own health issues. In addition to bringing innovative diagnostic technology to market, the Company’s ambition in that regard is to make diagnostics more accurate, easier to use and with precise and easily transferable results.

For more information, please visit Aegirbio’s website,

Certified adviser for the company is Eminova Fondkommission AB  | +468-684 211 00 |